Prostate Cancer

Latest News

June 26th 2013

Recent Progress on the Molecular Front for the Treatment of Prostate Cancer

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, discusses the recent progress for the treatment of prostate cancer.

June 17th 2013

Radium-223 in Advanced Prostate Cancer

By Saby George, MD, FACP

June 5th 2013

Case-Based Discussion: Integrating Novel Agents Into the Treatment of Prostate Cancer

By Beth Fand Incollingo

May 31st 2013

The Uses of Biomarkers in Prostate Cancer Trials

By Michael J. Morris, MD

May 28th 2013

Spotlight on Novel Agents in Early Development

By Anna Azvolinsky, PhD

Latest Videos

The Optimal Use of Identifying Genetic Risk Factors in Prostate Cancer

Metastatic Prostate Cancer with Charles Ryan, MD and William K. Oh, MD: Case 1

William Oh, MD: The Side Effects of Prednisone in Combination with Abiraterone

William Oh, MD: The Efficacy of Abiraterone Plus Prednisone in an Elderly Patient Population

William Oh, MD: Differences Between Side Effects of AR-Targeted Therapies

William Oh, MD: Ideal Treatment Options and Favorable Approaches

Charles Ryan, MD: The Side Effects for Prednisone in Combination With Abiraterone

Charles Ryan, MD: The Efficacy of Abiraterone Plus Prednisone in an Elderly Patient Population

Charles Ryan, MD: The Differences in Side Effects Between the Two AR-Targeted Therapies

Charles Ryan, MD: Treatment Options and Favorable Approaches for an Elderly Patient

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Seth A. Wander, MD, PhD; Kara M. Schenk, MD

Video

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Marla D. Lipsyc-Sharf, MD; Yan Ji, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

Video

43rd Annual Miami Breast Cancer Conference®

Patrick I. Borgen, MD; Reshma Jagsi, MD, DPhil; Hope S. Rugo, MD, FASCO

Multimedia

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Multimedia

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Multimedia

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Multimedia

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Multimedia

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

In-Person Event

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

May 22, 2026

Register now!

Multimedia

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Video

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

More News

Biomarkers Still Needed in Prostate Cancer

ByDevera Pine

May 21st 2013

Although biomarkers have been shown to correlate with survival in prostate cancer, the use of biomarkers in the management of these patients may be dependent upon the clinical state and the class of drug evaluated.

FDA Approves Radium-223 for Advanced Prostate Cancer

ByStaff Writer

May 15th 2013

Radium RA 223 dichloride has been approved by the FDA for the treatment of symptomatic metastatic castration-resistant prostate cancer (mCRPC) that has spread to the bones but not to any other organs.

Using Radium-223 Plus Docetaxel in Patients With Bone Metastasis From CRPC

ByMichael J. Morris, MD

May 15th 2013

Michael J. Morris, MD, discusses an ongoing phase I/IIa study looking at radium-223 with docetaxel in patients with bone metastasis from castration-resistant prostate cancer.

Utilizing CTCs in Solid Tumors

ByLeonard G. Gomella, MD

May 9th 2013

Leonard G. Gomella, MD, from the Kimmel Cancer Center, discusses the utilization of circulating tumor cells in patients with solid tumors.

Findings From the COU-AA-302 Trial

ByHoward I. Scher, MD

May 8th 2013

Howard I. Scher, MD, from the Memorial Sloan-Kettering Cancer Center, discusses an updated analysis of the COU-AA-302 trial.

The Role of Corticosteroids in Treatment Sequencing

ByWilliam K. Oh, MD

April 10th 2013

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses sequencing treatment in patients with metastatic castration resistant prostate cancer.